Precision BioSciences (DTIL) stock saw a 31% premarket surge after positive results from its gene therapy trial for treating ...

Climb Bio has entered an exclusive licence agreement with Beijing Mabworks Biotech for developing and commercialising the ...

INmune Bio's XPro targets neuroinflammation, showing promising biomarker results in Alzheimer's, with a potential to ...

Nuvie Bio, a new clinical-stage biopharmaceutical company dedicated to addressing the most pressing unmet medical needs in migraine and related neurological diseases, announced completion of a ...

ASN-008 is under clinical development by Formation Bio and currently in Phase II for Notalgia Paresthetica. According to GlobalData, Phase II drugs for Notalgia Paresthetica does not have sufficient ...

New Delhi: Prime Minister Narendra Modi on Thursday released the genome sequencing data of 10,000 Indian nationals.

Granexin is under clinical development by Xequel Bio and currently in Phase III for Radiodermatitis. According to GlobalData, Phase III drugs for Radiodermatitis does not have sufficient historical ...

Marea’s Phase IIa study enrolled patients with hypertriglyceridemia—too much fat in the blood. The latest results showed the ...

By bridging the gap between immersive technology and user-centric design, this research paves the way for a future where VR’s ...

Variant Bio is partnering with Novo Nordisk to study metabolic diseases including obesity, using Variant's genomic data from ...

Novo Nordisk will provide Variant with an upfront payment and additional near-term R&D funding that could reach up to $50m.

As market values increase for computational biology and data science, biopharma companies are looking to hire R&D ...